SAFC completes Jerusalem fermentation plant expansion

By Gareth Macdonald and Claire Videau

- Last updated on GMT

Related tags: Pharmacology, Active ingredient

SAFC has completed the expansion of its manufacturing plant in Jerusalem, Israel, further increasing its global footprint.

In an exclusive video interview, SAFC president Gilles Cottier and VP of contract manufacturing services Mark Cassidy told in-Pharmatechnologist that growing industry demand for high potency active pharmaceutical ingredients (APIs) was the key driver for the investment.

Cottier also explained that the addition of such capability is an important part of differentiating SAFC's offering in the increasingly competitive global contract manufacturing sector

The 50,000 expansion includes capacity for bulk drugs, secondary metabolites, cytotoxins and a range of large molecules proteins. SAFC has also installed additional

Related news

Show more

Related products

show more

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

SQ-USP-Brochure-Thumb-AP-CC

NEW…sugarcane derived USP Squalane from Aprinnova

APRINNOVA – A joint venture of AMYRIS and NIKKOL Group | 26-Feb-2018 | Product Brochure

To date, topical formulation chemists have been restricted to using Squalane derived from the harvesting of shark livers. Neossance Squalane USP, derived...

Related suppliers

Follow us

Products

View more